Pathak Ram D, Tran Tuan Huy, Burshell Alan L
Department of Internal Medicine, Section on Endocrinology and Metabolic Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA.
J Clin Endocrinol Metab. 2004 Feb;89(2):581-4. doi: 10.1210/jc.2003-031039.
A patient with a large prolactinoma developed a metastatic islet cell tumor secreting pancreatic polypeptide. Dopamine agonist drugs reduced the prolactin levels to normal, caused a 7-fold decrease in the pancreatic polypeptide levels, and inhibited the liver metastases. Elevated chromogranin A levels also normalized on the higher doses of bromocriptine. Dopamine receptors are found in many endocrine tissues, and the expression of dopamine-2 receptor on endocrine tumors establishes the potential for response to dopamine agonist treatment. The relatively benign risk profile of dopaminergic agents makes further testing of these drugs to treat neuroendocrine tumors a worthwhile endeavor.
一名患有大泌乳素瘤的患者发生了分泌胰多肽的转移性胰岛细胞瘤。多巴胺激动剂药物将催乳素水平降至正常，使胰多肽水平降低了7倍，并抑制了肝转移。在较高剂量的溴隐亭治疗下，嗜铬粒蛋白A水平升高也恢复了正常。多巴胺受体存在于许多内分泌组织中，内分泌肿瘤上多巴胺-2受体的表达确定了对多巴胺激动剂治疗产生反应的可能性。多巴胺能药物相对良性的风险特征使得进一步测试这些药物治疗神经内分泌肿瘤成为一项值得努力的工作。
